Holen Sie sich die Stockscreener-App
1.64
3.53%
-0.06
Handel nachbörslich:
1.75
0.11
+6.71%
Schlusskurs vom Vortag:
$1.70
Offen:
$1.69
24-Stunden-Volumen:
160.11K
Relative Volume:
0.33
Marktkapitalisierung:
$32.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.94M
KGV:
-0.4271
EPS:
-3.84
Netto-Cashflow:
$-22.97M
1W Leistung:
-4.09%
1M Leistung:
-36.92%
6M Leistung:
-79.53%
1J Leistung:
-81.96%
1-Tages-Spanne:
$1.61
$1.7299
1-Wochen-Bereich:
$1.525
$1.7727
52-Wochen-Spanne:
$1.525
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.64 | 32.93M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Annovis Bio stock hits 52-week low at $1.55 amid sharp decline - Investing.com Australia
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewswire
Revolutionary Parkinson's Treatment: Annovis Unveils Phase III Data for Multi-Target Drug - StockTitan
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.
Atria Wealth Solutions Inc. Purchases Shares of 13,002 Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio stock hits 52-week low at $1.72 amid market challenges - Investing.com Australia
ANVS ALERTLabaton Sucharow Announces the Filing of a Securities Class Action Against Annovis Bio, Inc.; Investors Encouraged to Contact the Firm Before October 18 - ACCESS Newswire
Annovis Bio stock hits 52-week low at $1.72 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio stock hits 52-week low at $2.42 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com Australia
Annovis to Host Patients’ Live Forum on February 27, 2025 - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Inside Annovis's Groundbreaking Alzheimer's Trial: CEO Opens Direct Dialogue With Patients - StockTitan
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap - MSN
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial - MSN
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN
Annovis Bio Inc. CEO to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on Pivotal Phase 3 Trial Progress - Nasdaq
Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - Hamilton Spectator
Annovis Bio (NYSE: ANVS) CEO To Present At Oppenheimer Healthcare Conference - Barchart
Annovis begins treatment of subjects in Alzheimer’s trial - Yahoo Finance
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial By Investing.com - Investing.com Australia
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Yahoo Finance
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
Annovis Bio sets terms for $21 million public offering - MSN
Annovis Bio completes $21 million stock and warrant offering - MSN
Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - Marketscreener.com
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):